Cowen and Company Reaffirms “Outperform” Rating for Humana Inc. (HUM)

Cowen and Company reaffirmed their outperform rating on shares of Humana Inc. (NYSE:HUM) in a research note published on Wednesday morning. Cowen and Company currently has a $275.00 target price on the insurance provider’s stock, up from their prior target price of $230.00.

Other research analysts also recently issued reports about the stock. BidaskClub raised shares of Humana from a sell rating to a hold rating in a report on Wednesday, August 23rd. ValuEngine raised shares of Humana from a hold rating to a buy rating in a report on Friday, September 1st. Argus raised shares of Humana from a hold rating to a buy rating and set a $260.00 price objective for the company in a report on Friday, June 9th. Zacks Investment Research raised shares of Humana from a hold rating to a buy rating and set a $255.00 price objective for the company in a report on Tuesday, June 13th. Finally, Morgan Stanley raised their price objective on shares of Humana from $269.00 to $276.00 and gave the stock an overweight rating in a report on Thursday, August 17th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the company. Humana has an average rating of Buy and a consensus price target of $246.60.

Shares of Humana (NYSE HUM) opened at 239.09 on Wednesday. Humana has a 52-week low of $163.50 and a 52-week high of $259.76. The stock has a 50 day moving average of $250.95 and a 200-day moving average of $232.23. The firm has a market capitalization of $34.55 billion, a P/E ratio of 19.67 and a beta of 0.87.

Humana (NYSE:HUM) last released its earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The firm had revenue of $13.53 billion during the quarter, compared to the consensus estimate of $13.61 billion. During the same period in the prior year, the firm earned $2.30 EPS. Equities analysts expect that Humana will post $11.55 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://ledgergazette.com/2017/09/23/cowen-and-company-reaffirms-outperform-rating-for-humana-inc-hum.html.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Tuesday, August 29th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 0.67%. The ex-dividend date is Thursday, September 28th. Humana’s dividend payout ratio (DPR) is currently 13.06%.

In related news, insider Elizabeth D. Bierbower sold 9,786 shares of Humana stock in a transaction on Friday, September 1st. The shares were sold at an average price of $259.00, for a total value of $2,534,574.00. Following the transaction, the insider now owns 18,042 shares in the company, valued at approximately $4,672,878. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Brian P. Leclaire sold 4,971 shares of Humana stock in a transaction on Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the completion of the transaction, the senior vice president now owns 14,258 shares in the company, valued at approximately $3,421,920. The disclosure for this sale can be found here. In the last quarter, insiders sold 60,566 shares of company stock worth $15,326,746. 0.80% of the stock is owned by corporate insiders.

Large investors have recently modified their holdings of the stock. WFG Advisors LP raised its position in Humana by 4.5% in the 2nd quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock worth $113,000 after purchasing an additional 20 shares during the period. Guardian Life Insurance Co. of America raised its position in Humana by 0.7% in the 1st quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock worth $119,000 after purchasing an additional 4 shares during the period. Acrospire Investment Management LLC purchased a new position in Humana in the 2nd quarter worth $120,000. Independent Portfolio Consultants Inc. raised its position in Humana by 22.1% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 519 shares of the insurance provider’s stock worth $125,000 after purchasing an additional 94 shares during the period. Finally, Point72 Asia Hong Kong Ltd purchased a new position in Humana in the 1st quarter worth $128,000. Institutional investors own 95.12% of the company’s stock.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply